ARTICLE | Company News
GlaxoSmithKline in-licenses Amira's FLAP inhibitors
February 5, 2008 2:34 AM UTC
Amira (San Diego, Calif.) granted GlaxoSmithKline (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to develop, manufacture and commercialize 5-lipoxygenase activating protein ( FLAP) inhibitors to treat respiratory and cardiovascular diseases. Inhibiting FLAP in turn inhibits cysteinyl leukotriene receptor 1 (CysLT1), CysLT2 and leuko-triene B4 type 1 receptor ( BLT1) in the leukotriene pathway. ...